• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

DeepIntent Outcomes Hits 65% of Campaign Impressions


DeepIntent, the leading healthcare advertising technology company built to influence better patient health and business outcomes, announced the significant adoption of its patented, award-winning advertising campaign measurement and optimization technology, DeepIntent Outcomes™. Since its launch in April 2021, DeepIntent Outcomes has been used to automatically optimize media based on real-world clinical data for 85 leading pharmaceutical brands, with over 50 brands benefiting from DeepIntent Outcomes year to date.

To prove business impact, IPG’s activation intelligence company, Matterkind, turned to DeepIntent Outcomes to maximize a client’s addressable media investment as measured by script volume and new-to-brand (NBRx) scripts. As the agency of record for the provider and patient sides of the business, Matterkind used script optimization and a mix of connected TV (CTV), online video, and display ads to reach audiences.

Using Outcomes to automatically optimize the campaign, Matterkind saw prescribing rates from healthcare providers increase by 10% after campaign exposure, and patients were 225% more likely to follow through in filling their prescriptions. Ultimately, the campaign grew NBRx by 12X while reducing the cost-per-script by 60%. In addition, channel analysis found that CTV ads were twice as effective as other channels in driving script performance.

Related Videos
Related Content